Roche considering divesting $1.9 bln cancer data startup, FT reports
Swiss pharmaceutical company Roche is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.
Roche ‘fast-tracking' weight-loss drug that rivals Wegovy
Pharmaceutical giant Roche is "fast-tracking" its own weight-loss pills in clinical trials as it looks to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years.
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Roche just reported some solid data with its weight loss pill program. Competitors might have a problem on the horizon as a result.
Roche to fast-track weight loss pill to compete with rivals, FT reports
Swiss pharmaceutical company Roche plans to fast-track its anti-obesity drugs to challenge Eli Lilly and Novo Nordisk after unveiling promising data for a weight-loss pill, the Financial Times reported on Monday.
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results
Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. Thomas Schinecker welcomed positive early stage trial results from its two weight loss drug candidates as showing "best in disease potential.
Roche lifts 2024 profit guidance on drug sales
Roche on Thursday raised its full-year earnings guidance, driven by high demand for newer drugs such as eye medicine Vabysmo.
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Roche's CT-996 pill could be a promising oral therapy to help individuals lose weight. Roche also has another injectable obesity drug in its pipeline that could potentially be best in class.
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
Roche's latest data update indicates one of its weight-loss programs is doing well. It has more than enough resources to bring its candidate to the market.
Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?
The stock price of Roche (OTCMKTS: RHHBY) is up 10% in a week, compared to around a 10% fall for its peer Eli Lilly stock (NYSE: LLY) over this period. The rise in Roche stock in recent days can primarily be attributed to the positive data for phase one clinical trial of its experimental obesity drug – CT-996.
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
